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Cytokine profiles show heterogeneity of
interferon-b response in multiple sclerosis
patients
ABSTRACT
Objective: To evaluate serum cytokine profiles for their utility to determine the heterogeneous
responses to interferon (IFN)–b treatment in patients with multiple sclerosis (MS).
Methods: Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome receiving
de novo IFN-b treatment were included in this prospective, observational study. Number of re-
lapses and changes in disability were assessed 2 years prior to and 2 years after initiation of
treatment. Sera were collected at baseline and after 3 months on therapy. Cytokine levels in sera
were assessed by Luminex multiplex assays. Baseline cytokine profiles were grouped by hierar-
chical clustering analysis. Demographic features, changes in cytokines, and clinical outcomewere
then assessed in the clustered patient groups.
Results: A total of 157 patients were included in the study and clustered into 6 distinct subsets by
baseline cytokine profiles. These subsets differed significantly in their clinical and biological
response to IFN-b therapy. Two subsets were associated with patients who responded poorly
to therapy. Two other subsets, associated with a good response to therapy, showed a significant
reduction in relapse rates and no worsening of disability. Each subset also had differential
changes in cytokine levels after 3 months of IFN-b treatment.
Conclusions: There is heterogeneity in the immunologic pathways of the RRMS population, which
correlates with IFN-b response. Neurol Neuroimmunol Neuroinflamm 2016;3:e202; doi: 10.1212/
NXI.0000000000000202
GLOSSARY
CIS 5 clinically isolated syndrome; CV 5 coefficient of variation; DMT 5 disease-modifying therapy; EDSS 5 Expanded
Disability Status Scale; HDMP 5 high-dose methylprednisolone; IFN 5 interferon; IL 5 interleukin; MCP1 5 monocyte
chemoattractant protein-1; MIP 5 macrophage inflammatory protein; MS 5 multiple sclerosis; MxA 5 myxovirus protein A;
NAb5 neutralizing antibodies;NMO5 neuromyelitis optica;RRMS5 relapsing-remittingmultiple sclerosis;SC5 subcutaneous;
sTRAIL 5 soluble tumor necrosis factor-related apoptosis-inducing ligand; sVCAM 5 soluble vascular cell adhesion molecule.
Relapsing-remitting multiple sclerosis (RRMS) is a heterogeneous disease that extends from clin-
ical course to underlying pathology.1,2 There is a wide variation in treatment response to ther-
apies including interferon (IFN)–b. Though neutralizing antibodies (NAb) against IFN-b are
associated with treatment failure,3 they only explain a part of nonresponsiveness. Hence, the
limited efficacy of IFN-b may be influenced by the heterogeneity of multiple sclerosis (MS).4
Many biomarker studies for IFN-b response assessed molecular differences in relation to a
clinical outcome.5–11 A common bifurcated result defines either responders or nonresponders by
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metrics based on relapses or disability. While
this methodology has identified some candi-
date biomarkers, these studies do not consider
disease heterogeneity.
Here, we measured serum cytokines from
patients with RRMS or clinically isolated syn-
drome (CIS) before the initiation of IFN-b
therapy (baseline) and at 3 months while on
therapy to assess their utility to predict treat-
ment response. For analysis, we used 3 ap-
proaches. The first 2 approaches compare
cytokines at baseline and 3 months in respond-
ers and nonresponders defined by relapses and
Expanded Disability Status Scale (EDSS) score,
respectively. The third approach uses the vari-
ability of baseline cytokine levels to cluster pa-
tients into subsets, and subsequently compares
clinical outcomes between these subsets.
METHODS Patients and specimens. The prospective Euro-
pean multicenter study Neutralizing Antibodies on Interferon-
beta in Multiple Sclerosis (NABINMS)12 enrolled patients with
CIS and patients with RRMS, as described previously.13 We
assessed cytokines from patients who had available data on
relapses 2 years prior to and 2 years after initiation of IFN-b
therapy, resulting in a total of 157 patients (table 1). Patients
received 1 of the 3 available IFN-b preparations: intramuscular
IFN-b-1a (Avonex), subcutaneous (SC) IFN-b-1a (Rebif), or SC
IFN-b-1b (Betaferon). Clinical assessments (number of relapses
and EDSS scoring14) were performed at baseline and 3, 12, and
24 months after initiation of therapy. Within the observation
period, a relapse was defined as patient-reported symptoms
(backed up by objective findings) or objectively observed signs
typical of an acute inflammatory demyelinating event with a
duration of at least 24 hours, in the absence of fever or infection.13
Number of relapses in the 2 years prior to study inclusion was
assessed at baseline visit, i.e., taken from patients’ charts together
with a profound anamnesis.
Serum and whole blood RNA samples were collected at base-
line, immediately before the first IFN-b injection, and at 3
months (62 weeks) within 4–12 hours postinjection.
Grouping of patients. Grouping of patients was performed as
follows: (1) According to relapse rate: Relapse nonresponders
were defined by having $1 relapse between baseline and 24
months. (2) According to EDSS score: EDSS nonresponders were
defined by showing an increase $1 EDSS point from baseline to
24 months. (3) Splitting patients into subsets by baseline cytokine
profile was achieved by clustering analysis. Subsequently, relapse
rate and change in EDSS score were compared between these
subsets.
Serum cytokine, NAb, and myxovirus protein A (MxA)
measurements. Luminex assays (eBiosciences/Affymetrix, San
Diego, CA) were performed at Stanford University according to
the manufacturer’s recommendations with modifications as
described in the e-Methods at Neurology.org/nn. NAb to IFN-
b and MxA mRNA expression were determined at Innsbruck
Medical University as described previously.12,15
Statistical and cluster analysis. For differences between
responders and nonresponders cytokine levels were log2-
transformed, and p values, odds ratios, and 95% confidence
intervals were calculated using logistic regression.
For cluster analysis of baseline cytokines, the coefficient of
variation (CV) of each cytokine in all serum samples was deter-
mined. Cytokines with CV values .100% were used to perform
hierarchical clustering of baseline samples. Using Gene Cluster
software,16 the cytokine values were normalized and centered to
the mean, then ordered by complete linkage clustering and pre-
sented as a heat map using TreeView.16
Differences in individual cytokine concentrations in the
resulting groups were assessed using Kruskal-Wallis with
Dunn multiple comparison tests. Differences of cytokines
between baseline and 3 months were analyzed using paired
t tests. Comparisons of baseline demographic and clinical fea-
tures within the clustered groups were performed using non-
parametric analyses of variance with Dunn multiple
comparisons or x2 tests. Changes in EDSS and number of
relapses between baseline and 24 months were assessed using
paired t tests.
Approvals and patient consents. The protocol was approved
by the ethic committees (approval number AM2538 239/4.8) of
all participating centers. Prior to any study-related investigations,
written informed consent was obtained from all patients. All
patient data were anonymized.
RESULTS Comparison of cytokines at baseline and
month 3 between responders and nonresponders defined
by relapses. Sixty-seven (42.7%) of 157 patients were
relapse nonresponders (table 1). Baseline clinical and
Table 1 Characteristics of the patient cohort
Variables Values
No. 157
Diagnosis, RRMS/CIS (% RRMS) 114/43 (72.6)
Age, y, mean (SD) 36.4 (8.7)
Disease duration, y, mean (SD) 4.8 (6.0)
Sex, F/M (% F) 108/49 (68.8)
HDMP use before BL, n (%) 116 (73.9)
Previous DMT use before BL, n (%) 15 (9.6)
IFN preparation, n (%)
IM IFN-b-1a 78 (49.7)
SC IFN-b-1b 36 (22.9)
SC IFN-b-1a 43 (27.4)
Time until 3-month visit, mo, mean (SD) 3.2 (0.6)
Time until 24-month visit, mo, mean (SD) 24.6 (3.9)
Relapse responders/nonresponders (% responders) 90/67 (57.3)
EDSS responders/nonresponders (% responders) 114/39a (74.5)
Abbreviations: BL 5 baseline; CIS 5 clinically isolated syndrome; DMT 5 disease-modifying
therapy; EDSS5 Expanded Disability Status Scale; HDMP5 high-dose methylprednisolone;
IFN 5 interferon; IM 5 intramuscular; RRMS 5 relapsing-remitting multiple sclerosis; SC 5
subcutaneous.
Relapse nonresponders were defined as having at least one relapse after IFN-b treatment
initiation. EDSS nonresponders were defined as having at least a 1-point increase in EDSS
score 2 years post initiation of IFN-b treatment.
aOf the 157 patients analyzed, 153 had sufficient clinical data to determine EDSS
responsiveness.
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demographic features of responders and nonresponders
showed no significant differences in disease type, age at
onset, disease duration, sex, EDSS, or drug type. We
observed that nonresponders had significantly greater
relapse rates prior to treatment compared to responders
(table e-1). Responders and nonresponders had similar
percentages of patients previously on a disease-
modifying therapy (DMT) and similar duration
between last high-dose methylprednisolone (HDMP)
use and initiation of IFN-b (tables e-1 and e-2).
We compared baseline serum cytokine levels
between relapse responders and nonresponders. We
observed that only interleukin (IL)–1b was signifi-
cantly different between these 2 groups (table e-3,
figure 1A).
We next compared changes in MxA mRNA (an
established surrogate for IFN-b bioavailability17)
and cytokine levels at 3 months vs baseline in relapse
responders and nonresponders. At 3 months, both
groups had significantly elevated levels of CXCL10/
IP10, CCL2/monocyte chemoattractant protein-
1 (MCP1), and MxA (figures 1, B and C, and e-1),
demonstrating that IFN-b is biologically active in
both responders and nonresponders.17–19 We also
found increases in IL-1a, soluble vascular cell
adhesion molecule (sVCAM)-1, and IFN-b in
responders and nonresponders (table e-4). Soluble
tumor necrosis factor-related apoptosis-inducing lig-
and (sTRAIL), granulocyte-colony stimulating factor,
transforming growth factor b, intercellular adhesion
molecule, IL-12p40, macrophage inflammatory pro-
tein (MIP) 1b, CD40L, IL-1RA, and MIP1a were
significantly elevated by IFN-b in responders but not
in nonresponders (figure 1D, table e-4). Finally, IL-8
was significantly decreased, while IFN-a and tumor
necrosis factor b were significantly increased at 3
months in the nonresponders but not the responders
(figure 1E, table e-4).
Frequency of NAb against IFN-b within 2 years
did not differ between relapse responders and non-
responders (9 of 90 and 7 of 67, respectively). How-
ever, levels of CXCL10/IP10 at 3 months were
significantly lower in patients who developed NAb
later on (NAbpos 147.1 6 29.3 pg/mL vs NAbneg
262.7 6 16.1 pg/mL, p 5 0.0082), thus confirming
that NAbs inhibit the biological response to IFN-b.12
Comparison of cytokines at baseline and month 3
between responders and nonresponders defined by
EDSS. Thirty-nine (25.5%) of 153 patients were
EDSS nonresponders (table 1). Baseline clinical and
demographic features showed no significant differen-
ces in disease type, age at onset, disease duration, sex,
number of previous relapses, or drug type. However,
responders had significantly greater EDSS score at
baseline and shorter duration between last HDMP
use to initiation of IFN-b compared to nonresponders
(table e-5). Responders and nonresponders had similar
percentages of patients previously on DMT (tables e-5
and e-6).
We compared baseline serum cytokine levels in
the EDSS responders and nonresponders. We found
that only monokine induced by interferon-g (MIG)
was significantly higher in the responders compared
to nonresponders (figure 1F, table e-7).
We next compared changes in cytokine and MxA
transcription levels (3 months vs baseline) in respond-
ers and nonresponders. We found that at 3 months
CXCL10/IP10, CCL2/MCP1, and MxA were signifi-
cantly elevated in both groups (figures 1, G and H, and
e-2); sTRAIL did not significantly change in the 2
groups (figure 1I); IL-8, plasminogen activator inhib-
itor–1, CXCL5/ENA78, and hepatocyte growth factor
were all significantly decreased in the responders but
not the nonresponders (figure 1J, table e-8); CD40L,
IL-17A, and nerve growth factor were significantly
increased in the responders but not the nonresponders;
and sVCAM was significantly increased in the non-
responders but not the responders (table e-8).
Baseline cytokine profiles cluster patients into 6 distinct
groups. Many cytokines including IL-1b do not have
a Gaussian distribution in our cohort (figure e-3),
suggesting there is heterogeneity in patients. We
hypothesized that selecting cytokines with the most
variability in the population could be used for clini-
cally meaningful stratification of patients. To select
the most variable serum cytokines, CVs of each cyto-
kine from all samples were calculated (table e-9).
Cytokines with a CV .100% were used for cluster-
ing of the patients’ baseline serum concentrations.
Clustering baseline cytokines split the patients
into 6 groups (figure 2A). Group 3 (n 5 20) had
significantly higher concentrations of IL-8, CXCL1/
Gro-a, IL-1b, IL-1RA, and CCL2/MCP1 compared
to all other groups (figure 2, B–F). Group 6 (n 5 8)
had significantly higher levels of IFN-b and IL-17F
compared to all other groups (figure 2, G–H). Cyto-
kines in group 2 (n5 53) were all low compared to all
other groups (figure 2A). Patients in group 1 (n5 23)
also had low cytokine levels except for CD40L, which
distinguished them from group 2 (figure 2, A and I).
The differences that distinguished groups 4 from 5
were more subtle. Group 4 (n5 37) had higher levels
of G-CSF and CD40L compared to group 5 (n5 16)
and conversely group 5 had higher levels of CXCL10/
IP10 and IL-6 compared to group 4 (figure e-4).
We found no significant differences in most base-
line clinical and demographic features of these 6
patient groups (table e-10). There was no statistical
difference in in the timing between HDMP and the
initiation of IFN-b within the groups. Also, we found
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that group 2 had statistically greater pretreatment dis-
ease duration and EDSS score compared to all other
patients (figure e-5). This difference is of note because
group 2 had low cytokine concentrations. There were
no statistical differences in patients with prior DMT
in each group (table e-11).
Differential clinical outcome to IFN-b treatment in the 6
clustered patient groups. First, we compared the
change in relapse rates 2 years prior to and 2 years
post initiation of IFN-b therapy. Groups 1, 2, 4,
and 5 all had significantly decreased relapse rates
while on IFN-b therapy, whereas there were no sig-
nificant changes in relapse rates in groups 3 and 6
(figure 3A). Furthermore, groups 1 and 5 had a low
percentage of patients with relapses while on therapy
compared to other groups; conversely, groups 3 and 6
had high percentages of patients who had relapses
(table e-12).
We next assessed worsening in disability from
baseline to 24 months. Groups 2 and 6 had signifi-
cant increases in EDSS; groups 3 and 4 had trends
suggesting increased EDSS; and groups 1 and 5
showed no worsening of EDSS after initiation of ther-
apy (figure 3B). Taking both relapse rates and EDSS
scores into account, these data suggest that groups
1 and 5 are populations that are likely to respond to
IFN-b therapy, whereas groups 3 and 6 represent
patients who are likely to be nonresponders. It is also
of interest that the patients in group 2, who had low
baseline cytokines and greater disease duration, had
increased EDSS while having decreased relapse rates.
We found no statistical differences in the fre-
quency of patients switching off IFN-b therapy or
developing NAb against IFN-b between the different
groups (table e-13).
Assessing baseline IL-7, IL-17F, and IL-17A in extreme
MS phenotypes. In a smaller study,20 we observed that
IL-7 and IL-17F levels were inversely correlated, that
patients with high IL-17F levels were nonresponders
and that patients with elevated IL-7 levels were
responders. Here, we found that groups 3 and 6
were 2 populations of nonresponders (figure 3). We
observed that group 6 had significantly higher IL-17F
levels, whereas group 3 had significantly higher IL-17A
levels compared to the other groups (figures 2 and 4, A
and B). Both IL-17A and IL-17F are signature TH17
cytokines,21,22 indicating that groups 3 and 6 have
extreme clinical phenotypes of nonresponsiveness with
a strong TH17 response. Groups 1 and 5 represent the
other end of the clinical extreme because almost all
patients in these 2 groups responded well to IFN-b.
When comparing IL-7 levels between groups 1 and 5 to
the rest of the patients withMS, we found that IL-7 was
significantly higher in group 5 compared to all other
patients (figure 4C). In our previous study,20 we
Figure 1 Comparison of serum cytokines in responders and nonresponders
defined by relapse rate or disability progression
(A)Comparison of baseline serumconcentrations of interleukin (IL)–1b in relapse responders (Resp)
and nonresponders (Nonresp). p Values were determined using a Student t test. The data repre-
sent themean6SEM.Changes in serumconcentrations of (B) CXCL10/IP10, (C) CCL2/monocyte
chemoattractant protein-1 (MCP1), (D) soluble tumor necrosis factor-related apoptosis-inducing
ligand (sTRAIL), and (E) IL-8 from baseline (BL) to month 3 (3M) in relapse responders and non-
responders. pValues were determined using a paired t test. The data represent the mean6 SEM.
(F) Comparison of baseline serum concentrations of monokine induced by interferon-g (MIG) in
Expanded Disability Status Scale (EDSS) Resp and Nonresp. p Values were determined using a
Student t test. The data represent the mean 6 SEM. Changes in serum concentrations of (G)
CXCL10/IP10, (H) CCL2/MCP1, (I) sTRAIL, and (J) IL-8 fromBL to 3M in EDSSResp andNonresp.
p Values were determined using a paired t test. The data represent the mean6 SEM.
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selected patients with extreme clinical responses to
IFN-b. It is likely that many patients selected for that
study would cluster in groups 5 and 6. We also assessed
soluble IL-7R at baseline in the clustered groups
and found no statistical differences (data not shown).
The new data from this larger cohort reinforce the
hypothesis that strong TH17 response is a
characteristic of nonresponders and that high IL-7 is a
characteristic of a subset of responders.
Differential biological effects of IFN-b treatment in the 6
clustered patient groups. MxA and CXCL10/IP10
were significantly elevated in all groups at 3 months,
demonstrating IFN-b bioavailability (figures 5A and
e-6). However, we found many differential changes in
other cytokines (table e-14). Groups 2, 4, and 5 had
significant increases in CCL2/MCP1, whereas groups
3 and 6 had no significant increase in this cytokine
(figure 5B). sTRAIL, which has been previously
associated with good response,23 was also differen-
tially affected by IFN-b treatment. sTRAIL was sig-
nificantly increased in groups 1 and 2, and,
conversely, significantly reduced in group 3 (figure
5C). There were also differential changes in IL-8,
CD40L, and IL-1a within the groups (figure 5,
D–F).
DISCUSSION Traditionally, biomarker studies assess
molecular differences in patient groups with clinically
defined outcomes. There are confounders that arise by
using this approach for biomarker studies. One con-
founder is how a study defines treatment response.
We found that defining response by relapse rates or by
EDSS progression results in different sets of biomarkers
Figure 2 Baseline serum cytokine profiles of patients with multiple sclerosis segregated by cluster analysis
(A) Heatmap depicts relative levels of cytokines and hierarchical clustering of individual patients. Baseline concentration of (B) interleukin (IL)–8, (C) CXCL1/
Gro-a, (D) IL-1b, (E) IL-1RA, (F) CCL2/monocyte chemoattractant protein-1 (MCP1), (G) interferon (IFN)–b, (H) IL-17F, and (I) CD40L in the groups of patients.
p Values were determined using Kruskal-Wallis test with Dunn multiple comparisons. *p , 0.05, **p , 0.01, ***p , 0.001.
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that predict treatment response. Another confounder is
that MS is heterogeneous and many biomarkers are
highly variable in the MS population. Here we utilized
the variability in serum cytokines to stratify patients into
subsets and learned that these subsets have distinct out-
comes to therapy.
Our first observation was that patients with low
cytokines (group 2) had longer disease duration and
greater EDSS before starting therapy compared to
the other patients (roughly 7 vs 4 years). This patient
group had significant reduction in relapses while hav-
ing increasing EDSS scores while on therapy. This
Figure 3 Clinical response to interferon (IFN)–b treatment in the different patient groups defined by baseline
cytokine profile
(A) Comparison of the number of relapses 2 years prior to (pre) and 2 years after initiation (post) of IFN-b therapy. (B)
Comparison of the Expanded Disability Status Scale (EDSS) score at baseline (BL) and 2 years after initiation of IFN-b
therapy. Statistical significance was determined with a paired t test with p , 0.05 considered significant. The data repre-
sent the mean 6 SEM.
Figure 4 Interleukin (IL)–17F, IL-17A, and IL-7 concentrations in responders and nonresponders returned by
baseline cytokine profile
(A) Comparison of pretreatment concentrations of IL-17F in patients in group 3, group 6 (nonresponders), and all other pa-
tients. (B) Comparison of pretreatment concentrations of IL-17A in patients in group 3, group 6 (nonresponders), and all
other patients. (C) Comparison of pretreatment concentrations of IL-7 in patients in group 1, group 5 (responders), and
all other patients. p Values were determined using a Kruskal-Wallis test with Dunnmultiple comparisons. The data represent
the mean 6 SEM.
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observation suggests that these patients, who are in a
later disease stage, have fewer inflammatory events
and are closer to the progressive disease phase.24
The other groups were in an early disease phase,
where relapses may be an informative measure.
Our second observation was that there are 2 dis-
tinct baseline cytokine profiles that correlate with
nonresponsiveness defined by a lack of reduction in
relapses. One subset of nonresponders (group 3)
had high levels of IL1b, IL-8, CXCL1/Gro-a,
CCL2/MCP1, and IL-17A. This confirms a recent
report that increased baseline levels of IL-1b is
observed in IFN-b nonresponders.7 IL-1b is required
for differentiation of human TH1725,26 cells and, fur-
thermore, IL-8, CXCL1/Gro-a, and CCL2/MCP1
are chemokines induced by IL-17 signaling, indicat-
ing that the TH17 pathway is elevated in these pa-
tients.27,28 The second subset of nonresponders
(group 6) had elevated IL-17F, which is similar to a
subset of nonresponders described in a smaller cohort
of patients.20,29 Other authors reported that IL-17F
levels were not statistically different in responders and
nonresponders5,6; however, they did not consider het-
erogeneity of MS for their analyses. These studies
predefined treatment response by combining the 2
clinical measures relapse rate and EDSS score and
Figure 5 Change of serum cytokines during early interferon (IFN)–b treatment in patients with multiple sclerosis segregated by cluster
analysis
Changes in serum concentrations of (A) CXCL10/IP10, (B) CCL2/monocyte chemoattractant protein-1 (MCP1), (C) soluble tumor necrosis factor-related
apoptosis-inducing ligand (sTRAIL), (D) interleukin (IL)–8, (E) CD40L, and (F) IL-1a from baseline (BL) to month 3 (3M) in the patient groups defined by
baseline cytokine profiles. p Values were determined using a paired t test. The data represent the mean 6 SEM.
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simply compared cytokine concentrations. This
might be the reason why the influence of IL-17F
on treatment response was not seen.6 There is a strik-
ing similarity between these 2 subsets of nonrespond-
ers; both have characteristics of a TH17 response.
One subset of nonresponders has high levels of
IL-17A and chemokines induced during a TH17
response. The other subset of nonresponders has high
IL-17F, a signature cytokine of TH17 cells.21,22 It is
unclear if these 2 subsets of nonresponders represent
different TH17 pathways, or indicate different stages
of a TH17 response or whether the TH17 cells are
transdifferentiating into either TH1 or Tregs.30,31 It
has been shown that TH17 cytokines and granulo-
cyte chemokines are elevated in patients with neuro-
myelitis optica (NMO), a neuroinflammatory disease
not responding to IFN-b therapy,32–35 suggesting that
the disease processes in these subsets of IFN-b non-
responding patients with MS are similar to NMO and
in future studies perhaps such patients should be
tested for NMO immunoglobulin.
Our third observation was that there are 2 distinct
profiles that distinguish IFN-b responders: patients
with a reduction in relapse rates and no worsening in
EDSS. One subset of responders, group 1, had low
concentrations of all cytokines except CD40L. We
speculate that this subset has a milder inflammatory
response that is effectively treated with IFN-b. The
other subset of responders (group 5) had high levels of
IL-7 compared to the other MS subsets. The protec-
tive effects of IL-7 during IFN-b treatment are not
entirely clear. However, we and others have found
that IL-7 promotes TH1 differentiation and IFN-g
expression.20,36 These data suggest the hypothesis that
IFN-b has anti-inflammatory effects during an IL-7-
driven TH1 response and conversely has inflamma-
tory effects during a TH17 response.
Finally, each patient group upregulated MxA
and CXCL10/IP10 at 3 months after start of IFN-b
therapy, demonstrating its bioavailability.17,18 This
shows that all patient subsets responded biologically
to IFN-b but that the differential characteristics of
the subsets influence therapeutic efficacy.
There are potential limitations of this study.
Approximately 10% of patients were previously on
other therapies. This is only a small proportion and
the number of pretreated patients did not differ
between groups. Therefore, it is unlikely that this af-
fects our findings. This similarly applies to the low
proportion of patients with CIS, which also did not
differ between the groups. Furthermore, a certain
imbalance of baseline clinical data between groups,
e.g., higher prior relapse rate in relapse nonrespond-
ers, is likely not relevant as we used the change of
cytokine profile between baseline and 3 months while
on therapy for evaluation of treatment response. As
group 2 showed overall low cytokine levels, possibly
due to the longer disease duration, one might specu-
late that a certain differential regulation of these cyto-
kines is obscured. Finally, some samples were
collected over 5 years prior to analysis. Therefore,
there is potential for protein degradation. However,
we did not see differences in cytokine profiles related
to the long-term storage.
The heterogeneous nature of RRMS was notably
described previously where subgroups of patients
with RRMS were identified with differences in
immunopathologic patterns in lesions.1,2 Our data
from serum cytokines provide more evidence for
immunologically distinct subgroups of MS and sug-
gest these subgroups can stratify treatment response.
Such stratification provides evidence that biomarkers
can be informative for prognosis and treatment
response. Further studies that include additional lon-
gitudinal samples as well as MRI data are warranted.
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